Doctors rethinking prescribing Abbott’s Niaspan
Doctors say they are thinking twice about prescribing an Abbott Laboratories drug used to raise levels of good cholesterol to patients taking a statin pill that is successfully lowering their bad cholesterol. The change of heart by physicians about the need for Abbott's Niaspan follows the release last week of a National Institutes of Health study that showed the drug failed to prevent heart attacks and slightly raised the risk of a stroke when combined with the popular generic cholesterol pill simvastatin, also known by the brand name Zocor. Doctors say statins, including simvastatin, Lipitor and Crestor, do such a good job at lowering LDL, or bad cholesterol, that there's often little need to add another pill to most patients' treatment. And the study is giving them more reason not to add Niaspan, which raises HDL, or the good stuff.
- Urologists 'Outraged' Over PSA Test Challenge
- New Facebook Page Gathers Stories of Medical Harm
- Luxury Hospital Facilities Put Patient Experience First
- Five Hospitals Share Three Secrets to Improve Knee Surgery Outcomes
- Heartland Health Joins Mayo Clinic Network
- Health Insurance Exchanges Put Defined Benefits to the Test
- Beleaguered Fairview Health CEO to Retire in July
- How Rivals Built an ACO
- Challenging Physicians to Help Improve the ED
- TN Health System Charts Its Own Course

